This lecture was part of a CME accredited symposium: PCSK9 inhibition in clinical lipid management: A critical review of evidence and opportunities held at ESC 2016 in Rome

• PCSK9 as a target for pharmacotherapy 00:25
• Indications for PCSK9 inhibitors 02:30
• Novel insights in the diagnosis and management of FH to date 03:49
• PCSK9 inhibitors in the management of FH: RUTHERFORD-2 (evolocumab) 05:14
• The Odyssey Program (alirocumab) 07:39
• LDL-C levels in FH: From a lethal disorder to a manageable dyslipidemia 10:14

Educational information

Educational objectives of this symposium were to:

• Understand the unmet need for additional LDL-C-lowering therapies beyond current optimal statin-based therapy as a strategy for addressing lipid-related CV risk in patients at increased CV risk and with FH
• Understand the mechanisms and potential applications of emerging therapies to lower LDL through novel approaches that can be used in combination with statin therapy
• Describe the potential impact of PCSK9-based therapies in development in patients who require additional LDL-C reduction
• To explore treatment options in a statin-intolerant high risk patient in order to reach LDL-C goal
• Compare and evaluate evidence from recent clinical trials of novel agents in clinical development and assess their impact on lipids and cardiovascular risk
• Emphasize the need for outcomes data from clinical trials to apply implications and recommendations for practical lipid management

-Understand the implications of new ESC guidelines for lipid management

CME accreditation

This programme is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit(s).

Faculty & Disclosures

Prof. John J.P. Kastelein is Professor of Medicine and chairman of the Department of Vascular Medicine at the Academic Medical Center (AMC) of the University of Amsterdam, where he holds the Strategic Chair of Genetics of Cardiovascular Disease

Funding

Supported by unrestricted educational grants from Amgen, Pfizer, and Sanofi-Regeneron.

Also watch lecture: PCSK9, the short track road from discovery as drug target towards the clinic, by Gilles Lambert, MD – Université de la Réunion, Sainte-Clotilde, France Also watch lecture: A clinical perspective on PCSK9 inhibition: What do we know an what can we expect? by Paul M Ridker, MD – BWH, Harvard Medical School, Boston, MA, USA